Open AccessAbacavir and Metabolite Pharmacokinetics in HIV-1-Infected Children and Adolescents
Author(s) -
Shane J. Cross,
John H. Rodman,
Jane C. Lindsey,
Brian L. Robbins,
Charles H. Rose,
Geoffrey J. Yuen,
Lawrence J. D’Angelo
Publication year - 2009
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e31819a2257
Subject(s) - pharmacokinetics , abacavir , cmax , medicine , metabolite , population , human immunodeficiency virus (hiv) , gastroenterology , viral load , antiretroviral therapy , immunology , environmental health
Abacavir (ABC) oral clearance, adjusted for body size, is approximately 2 times higher for children than adults with a corresponding difference in dose regimens. However, there are limited data available in the adolescent population. The pharmacokinetics (PKs) of ABC and primary metabolites were determined in HIV-1-infected children and adolescents to evaluate age and patient characteristics as a basis for adjusting ABC dose regimens and to assess the influence of metabolite formation on PK parameters.